This is a regulatory disclosure submitted to the BSE Limited and the National Stock Exchange of India Limited.
The Board of Directors of Windlas Biotech Limited is scheduled to meet on Monday, August 10, 2026. The primary agenda for this meeting is to consider and approve the company's unaudited standalone financial results for the quarter ended June 30, 2026 (Q1 FY2027). This notice is issued pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The disclosure also confirms that the Trading Window for the company's Designated Persons has been closed since July 1, 2026, as communicated in a previous letter dated June 25, 2026. This closure is in compliance with the company's code of conduct under the SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window is scheduled to reopen 48 hours after the financial results are declared to the public.
The letter is signed by Ananta Narayan Panda, who holds the designation of Company Secretary & Compliance Officer.
Financial Impact
Financial results for the quarter are pending board approval. The impact of the results will be known post the board meeting and subsequent announcement.